Cs-131前列腺近距离放疗后患者报告的远期直肠出血与肠道相关生活质量
基于620例接受Cs-131前列腺近距离放疗患者的前瞻性数据库,中位随访48个月,临床显著远期直肠出血累积发生率为12.4%,末次随访时患病率为4.0%。多因素分析显示外照射联合治疗(HR 2.50)和急性直肠出血(HR 3.11)是远期直肠出血的显著预测因素。
要点
- 中位随访48个月,临床显著远期直肠出血累积发生率12.4%,末次随访患病率降至4.0%。
- 外照射联合治疗(HR 2.50,95%CI 1.58-3.94)和急性直肠出血(HR 3.11,95%CI 1.75-5.53)为独立预测因素。
- 临床显著出血困扰累积发生率15.2%,末次随访患病率4.7%。
核心结论
- Cs-131前列腺近距离放疗远期耐受性良好,临床显著患者报告远期直肠出血虽累积发生率达12.4%,但末次随访患病率仅4.0%,提示该问题趋于缓解。
研究设计与样本
- 回顾性分析前瞻性收集的620例接受Cs-131前列腺近距离放疗患者数据库,其中390例(62.9%)为单药治疗,其余联合外照射放疗。
主要发现
- 中位随访48个月,临床显著远期直肠出血累积发生率为12.4%,临床显著出血困扰累积发生率为15.2%。
- 末次随访时,临床显著直肠出血患病率为4.0%,临床显著出血困扰患病率为4.7%。
- 单因素分析中,急性临床显著直肠出血(发生于前6个月内,P=.001)和联合外照射治疗(P=.001)预测临床显著远期直肠出血。
- 多因素分析中,外照射联合治疗(P=.001;HR 2.50;95%CI 1.58-3.94)和急性直肠出血(P<.001;HR 3.11;95%CI 1.75-5.53)仍为远期直肠出血的显著预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is limited long-term data on outcome and side effects of Cs-131 prostate brachytherapy and minimal patient-reported data on rectal bleeding with any isotope. We aimed to describe the incidence, prevalence, and predictors of late patient-reported rectal bleeding after Cs-131 brachytherapy. METHODS AND MATERIALS: We reviewed a prospectively collected database of 620 men treated with Cs-131 prostate brachytherapy. Of 620 patients, 390 (62.9%) received brachytherapy as monotherapy; the remainder received combination therapy with external beam radiation therapy (EBRT). Patients were administered Expanded Prostate Cancer Index Composite questionnaires preoperatively and postoperatively at each follow-up visit. The primary outcome was late rectal bleeding, defined as rectal bleeding reported at the 6-month follow-up or later. Clinically significant rectal bleeding was defined as occurring more than "rarely," and clinically significant bother from rectal bleeding was defined as considering bleeding more than a "very small problem." Univariate and multivariate Cox regression were performed to identify factors predictive for rectal bleeding. RESULTS: With a median follow-up time of 48 months, the cumulative incidence of clinically significant late rectal bleeding was 12.4%, with 15.2% reporting clinically significant bother from bleeding. At the time of last follow-up, the prevalence of clinically significant rectal bleeding and bother were 4.0% and 4.7%, respectively. On univariate analysis, acute clinically significant rectal bleeding, defined as occurring within the first 6 months (P = .001) and combination therapy with EBRT (P = .001) predicted for clinically significant late rectal bleeding. On multivariate analysis, both EBRT (P = .001; hazard ratio, 2.50; 95% confidence interval, 1.58-3.94) and acute rectal bleeding (P < .001; hazard ratio, 3.11; 95% confidence interval, 1.75-5.53) remained significant predictors for late rectal bleeding. CONCLUSIONS: Prostate brachytherapy with Cs-131 is well tolerated in the long term. Although the incidence of clinically significant patient-reported late rectal bleeding was 12.4%, the prevalence at last follow-up was only 4.0%, suggesting that this problem tends to resolve.
引用
- Ling DC, Chen KS, Benoit RM, et al. Long-Term Patient-Reported Rectal Bleeding and Bowel-Related Quality of Life After Cs-131 Prostate Brachytherapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 30853423. doi:10.1016/j.ijrobp.2019.02.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。